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ADC predicted poor histologic tumor response (TRG3–5 versus 
TRG1–2) with 91% sensitivity and 83% specificity (area under 
curve (AUC)=0.89, 95% confidence interval (CI)=0.74–1.0, 
p=0.001). Using the 30th percentile, an increase in ADC 
predicted poor PFS with 89% sensitivity and 71% specificity 
(AUC=0.75, 95% CI=0.54–0.95, p=0.051). Univariate regression 
analysis also revealed that the ADC increase was significantly 
associated to poor PFS (hazard ratio=9.7, 95% CI=1.21-78.30, 
p=0.033). 
 
Conclusion: By ADC histogram analysis of DWMRI acquired 
during NACT of LARC we identified low histogram percentiles 
as predictive of histologic tumor response in particular, but 
also long-term survival. The results require validation in 
larger, independent cohorts, but are promising for 
identification of patients that may benefit from 
individualized treatment approaches for improved disease 
outcome. 
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Purpose or Objective: Tumor hypoxia is prognostic for poor 
outcome after radiotherapy (RT). A method for non-invasive 
assessment of hypoxia is PET using hypoxia radiotracers such 
as FMISO. The goal of this study was to develop and evaluate 
a tool to simulate 3D oxygen distribution and the resulting 
FMISO accumulation on realistic vessel architectures, which 
can be compared to measured PET activities in small animal 
experiments. 
 
Material and Methods: Two FaDu tumors (human HNSCC) 
were grown on the right hind leg of nude mice. Imaging was 
performed after a growth phase of about 5 weeks. FMISO was 
injected into the tail vein of the anesthetized mice with an 
activity of ~12MBq for dynamic PET/MRI. ROIs inside the left 
ventricle and in the tumor were chosen to determine blood 
and tumor time activity curves (TACs). After image 
acquisition tumors were excised, snap frozen and cut into 
consecutive sections (20µm). Sections were stained with 
immunoflourescence-labeled antibodies for endothelial 
marker CD31 and scanned with a Zeiss Axioplan 2 
fluorescence microscope. Obtained immunofluorescence 
images were rigidly registered, manually adjusted and 
thresholded to create a binary 3D vessel map. These maps 
were used to simulate 3D oxygen distributions based on a 
Michaelis-Menten relation. Using the oxygen distribution and 
the dynamic activity in the left ventricle as input, FMISO 
retention was simulated on the same vessel maps. A tumor 
ROI was selected and its average activity at different time 
points post-injection (p.i.) compared against the measured 
activity in the same region on the PET scan (tumor TAC). To 
compare 3D and 2D simulations, the simulation were 
repeated in 2D on the individual sections, and 2D-based 
oxygen histograms and TACs were determined. 
 
Results: O2 histograms showed a large difference between 
2D and 3D simulations, with much lower values for 2D 
simulations than for 3D (5.94 mmHg vs 26.57 mmHg). Mean 
values were closer together (8.9 mmHg vs 13.2 mmHg). This 
is due to the large amount of anoxic voxels (pO2 < 1 mmHg) 
in the 2D simulation, which made up 17.5% of all simulated 
voxels in 2d, but less than 1% in the 3D simulations (see Table 
1). Visually, the 3D simulations result in a TAC with a similar 
overall shape compared to the TAC measured with small 
animal PET, but with a 20.7% overestimation of activity. 
However, the 2D simulations severely overestimated the total 
activity by 99.2% (2D) when compared against measured 
activity in the tumor after 90min as determined by PET. 
 
 
Conclusion: 3D simulations based on real 3D vessel 
architecture is feasible. Our FMISO simulations showed large 
discrepancies between 2D and 3D simulation approaches, 
with the 3D values being closer to the PET measurements. 
Verification of 3D tracer accumulation patterns in additional 
tumors against pimonidazole stainings is still necessary to 
validate and calibrate the method, with PET scans in the 
same test subject to confirm observed activity. 
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Purpose or Objective: Tumorcontrol of primary prostate 
cancer (PC) is dose dependent. Dominant index lesions (DIL) 
within the prostatic gland are responsible for local and 
distant failure. Radionuclide-labelled inhibitors of prostate-
specific membrane antigen (PSMA-PET) showed promising 
preclinical and clinical results in detection of primary 
prostate cancer. We correlated PET/histopathology using a 
new coregistration approach, which allows pixel-wise 
evaluation of the tracers performance in prostatic tissue. Aim 
of this work is to evaluate the diagnostic accuracy of 68Ga-
PSMA-PET/CT and to determine potential SUV-thresholds 
enabling a focal dose escalation on DIL delineated by PET. 
 
Material and Methods: 10 patients with primary PC and 
68Ga-PSMA-PET/CT were enrolled. After prostatectomy, 
thorough histopathological preparation and anatomical-based 
coregistration between in-vivo and ex-vivo material was 
performed. Simulated PET-images were generated out of 
blurred 3D histopathological tumor distribution (histoPET). 
The coregistration was further optimized by matching 
histoPET information with the in-vivo PET signal. The tracer 
performance was evaluated by coefficient of determination 
(R²) between histoPET/PSMA-PET patterns and SUV-values 
within different tissue types. 
 
Results: 1 patient was excluded due to imprecise 
pathological preparation. Mean R² value was 60 % (± SD 15.2, 
range: 42.5-81.6). SUVmax of PSMA-PET was located in non 
resolution adapated / resolution adapted PC-tissue in 
80%/90% of patients. Mean SUVmean in non resolution 
adapted PC and non-PC tissue was 6.1 (range: 2 – 21) and 2.7 
(range: 1.3 – 8.2), respectively. The ratio between SUVmean 
in PC / non-PC was 2.2 (SD ± 0.6). 
 
